JP2021104956A - Agent for preventing or improving onset of premenstrual syndrome - Google Patents

Abstract

To provide an agent effective as an agent for preventing or improving the onset of PMS.SOLUTION: An agent for preventing or improving onset of premenstrual syndrome contains Angelica acutiloba powder, Paeonia lactiflora powder, and Cnidium rhizome powder. The agent can eliminate or reduce the onset of PMS symptoms.SELECTED DRAWING: None

Description

The present invention relates to a preventive or ameliorating agent for the onset of premenstrual syndrome.

Premenstrual syndrome (PMS) is a mental or physical symptom that continues during the luteal phase of 3 to 10 days before menstruation and declines or disappears with the onset of menstruation, according to the Japan Society of Obstetrics and Gynecology. It is defined.

In women with a menstrual cycle, a large amount of estrogen (follicle hormone) and progesterone (luteal phase) are secreted during the period from ovulation to menstruation (luteal phase), but follicular hormone and progesterone rapidly increase in the latter half of this luteal phase. descend. PMS is thought to develop by causing abnormalities in hormones and neurotransmitters in the brain, triggered by such rapid fluctuations in hormones. Mental or physical symptoms caused by PMS may interfere with daily life to some extent, and appropriate treatment is required.

As a treatment for PMS, there is a symptomatic treatment that alleviates the symptoms by diet and exercise, but in many cases, a drug is selected. Drugs include analgesics, anti-nausea, intestinal regulators, swelling-improving drugs, vitamins, amino acid preparations, nourishing tonics, sleep-inducing agents, tranquilizers, and other drugs that directly address specific symptoms caused by PMS. On the other hand, there is also hormone replacement therapy that focuses on changes in female hormones that cause PMS.

In addition to the above-mentioned drugs, Chinese herbs may be selected as the drugs used for PMS. Specifically, such Chinese herbs include Goreisan extract, Tokakujokito extract, and Tokishakuyaku. Examples include Shakuyakusan extract. Of these, Goreisan extract is used for swelling, and Tokakujokito extract is used for persistent constipation and abdominal tension. On the other hand, Tokishakuyakusan extract is known as a Chinese herbal preparation having an estrogen-like action (Non-Patent Document 1), and is therefore used as an alternative to hormone replacement therapy to alleviate the effects of hormone fluctuations.

Biol Palm Bull 2008, 31 (6), p. 1145-1149

Drugs used for the purpose of hormone replacement for PMS show a peculiar effect on the state of rapid hormone decrease in the menstrual cycle, so they are taken at the time when PMS is actually occurring. It is a natural premise to do. There is a peculiar hormonal state in a woman's menstrual cycle, and the hormonal state is different in each of the follicular phase, ovulation phase and luteal phase. It makes no sense to have the above medications taken at different times. For this reason, with regard to drugs intended to deal with PMS, it is premised that they are taken only at the time when PMS is actually occurring, and the onset of PMS is eliminated (prevention of onset) or the onset of PMS occurs. Until now, there was no idea of gradual (improvement of onset).

The present inventor has conceived in advance a novel use of a drug for dealing with PMS, which is prevention or improvement of the onset of PMS itself, in order to enhance the effect of suppressing the symptoms of PMS.

Therefore, an object of the present invention is to provide an agent effective as a preventive or ameliorating agent for the onset of PMS.

As a result of diligent studies, the present inventors have found that a crude drug powder preparation containing Angelica acutiloba powder, Peony powder, and Senkyu powder is effective as a preventive or ameliorating agent for PMS. This is completely unexpected in view of the fact that Tokishakuyakusan, an extract of mixed crude drugs containing Angelica acutiloba, Peony and Senkyu, is effective at the onset of PMS by a mechanism of action that alleviates the effects of hormonal fluctuations. Met. The present invention has been completed by further studies based on this finding.

That is, the present invention provides the inventions of the following aspects.
Item 1. A preventive or ameliorating agent for the onset of premenstrual syndrome, which contains powdered Angelica acutiloba, powdered peony, and powdered peony.
Item 2. Item 2. The preventive or ameliorating agent for the onset of premenstrual syndrome according to Item 1, wherein administration is started from any day from the follicular phase to the ovulation phase.
Item 3. Item 3. The agent for preventing or improving the onset of premenstrual syndrome according to Item 1 or 2, which is an agent for improving the constitution of premenstrual syndrome.
Item 4. Item 3. The agent for preventing or ameliorating the onset of premenstrual syndrome of premenstrual syndrome, which is taken continuously for 3 or more cycles of the menstrual cycle.
Item 5. The premenstrual syndrome according to any one of Items 1 to 4, further containing a crude drug powder selected from the group consisting of rhubarb powder, sojutsu powder, cinnamon powder, buttonpi powder, rhubarb powder, tounin powder, carrot powder, and taksha powder. A preventive or ameliorating agent for the onset of syndrome.

According to the present invention, since an agent effective as a preventive or ameliorating agent for the onset of PMS is provided, an excellent effect is exerted on the prevention or amelioration of the onset of PMS.

The dosing schedule in Example 1 is shown. In the figure, "egg" indicates the follicular phase, "ovulation" indicates the ovulation phase, "yellow" indicates the luteal phase, and the continuous period of "egg", "ovulation" and "yellow" is defined as one cycle of the menstrual cycle. show. The same applies to FIGS. 2 and 3. The dosing schedule in Comparative Example 1 is shown. The dosing schedule in Example 2 is shown.

The preventive or ameliorating agent for the onset of premenstrual syndrome of the present invention is characterized by containing Angelica acutiloba powder, Peony powder, and Senkyu powder, and is used for women after menopause. Hereinafter, the preventive or ameliorating agent for the onset of premenstrual syndrome of the present invention will be described in detail.

Active ingredient

Angelica acutiloba (Angelica acutiloba) is the root of Angelica acutiloba Kitagawa or other related plants of the Umbelliferae family, and is usually boiled in hot water. It is used in combination with prescriptions for tonics, neuropsychiatric drugs and urinary tract diseases. Angelica acutiloba powder is commercially available from Maruzen Pharmaceuticals Co., Ltd., Sangoku Co., Ltd., Ichimaru Falcos Co., Ltd., etc.

Peony (peony) is the root of peony Paeonia lactiflora Pallas or other related plants of the Peony family (Peonyaceae), and is mainly used as a crude drug (Japanese Pharmacopoeia) for analgesic and antispasmodic (gastrointestinal), women's medicine, and cold medicine. Used for applications such as peony. Peony is both a crude drug name (Japanese Pharmacopoeia) and a plant name. Peony powder is commercially available from Maruzen Pharmaceuticals Co., Ltd., Sangoku Co., Ltd., Ichimaru Falcos Co., Ltd., etc.

Senkyu is usually blanched rhizomes of Cnidium office Makino of the Umbelliferae family, and is mainly used as a crude drug (Japanese Pharmacopoeia) for vascular reinforcements, women's medicines, and the like. Senkyu is both a crude drug name (Japanese Pharmacopoeia) and a plant name. Senkyu powder is commercially available from Nippon Powder Chemicals Co., Ltd., Tochimoto Tenkaido Co., Ltd., etc.

The content of Angelica acutiloba powder, Peony powder, and Senkyu powder in the preventive or ameliorating agent for the onset of premenstrual syndrome of the present invention is not particularly limited, but for example, the total amount is 10 to 98% by weight, preferably 13 to 95% by weight. , More preferably 16-85% by weight. In addition, the ratio of the contents of Angelica acutiloba powder, Peony powder, and Senkyu powder to 100 parts by weight of the total crude drug powder contained in the preventive or ameliorating agent for the onset of premenstrual syndrome of the present invention is, for example, 20 to 98 parts by weight in total. It is preferably 28 to 95 parts by weight, more preferably 34 to 85 parts by weight.

The ratios of Angelica acutiloba powder, Peony powder, and Senkyu powder are not particularly limited, but Angelica acutiloba powder: Peony powder: Peony powder = 1: 0.5 to 1.7: 0.4 to 1, preferably 1: 0. 8 to 1.2: 0.6 to 0.8, and particularly preferably 1: 1: 2/3.

Other Crude Drug Ingredients The prophylactic or ameliorating agent for the onset of premenstrual syndrome of the present invention can be used as other herbal medicines as other herbal medicines, such as cinnamon powder, cinnamon powder, cinnamon powder, and buttonpi powder. It is preferable to further contain one or more kinds of crude drug powders selected from the group consisting of powders of daiou, powders of tounin, powders of carrots, and powders of taksha.

Bukuryo (Polyporaceae) is a sclerotium of the Chinese root Wolfiporia cocos Ryvarden et Gilbertson (Polia cocos Wolf) of the Polyporaceae family. , Used for diuretics, etc. Bukuryo powder is commercially available from Takasago Yakuhin Co., Ltd., Tochimoto Tenkaido Co., Ltd., etc.

Atractylodes lanceolata is a rhizome of Atractylodes lancea De Candle or Atractylodes chinensis Koidzumi of the Asteraceae family, and is mainly used as a crude drug (Japanese Pharmacopoeia). Sojutsu powder is commercially available from Tochimoto Tenkaido Co., Ltd., Yoshimi Pharmaceutical Co., Ltd., etc.

Cinnamon cinnamon cassia Blum of the Lauraceae family or other plants of the same genus is peeled from the bark of the thick trunk of cinnamon, and is mainly used as a crude drug (Japanese Pharmacy) for aromatic stomachic medicine. Will be done. Cinnamon powder is commercially available from Nippon Powder Chemicals Co., Ltd., Tochimoto Tenkaido Co., Ltd., etc.

Peony bark is the root bark of Peonya sufruticosa Andrews (Paeonia moustan Sims) of the Peony family, and is mainly used as a crude drug (Japanese Pharmacopoeia) for women's medicines and the like. Buttonpi powder is commercially available from Tochimoto Tenkaido Co., Ltd., Takasago Pharmaceutical Co., Ltd., etc.

Rhubarb (Rhubarb) is a member of the Polygonaceae family, Rheum palmatum L. et al. , Rheum tanguticum Maximowicz, Rheum office Ballon, Rheum coreanum Nakai or their interspecific hybrids, which are usually rhizomes and are mainly used as crude drugs (Japanese Pharmacopoeia) for stomachic and laxatives. Rhubarb powder is commercially available from Sanwa Crude Drug Co., Ltd., Tochimoto Tenkaido Co., Ltd., etc.

Tounin (Peach Jin) is a peach of the Rosaceae family (Plumus persi-ca Basch) or Prunus persica Basch var. It is a seed of davidiana Maximowicz and is used as a crude drug (Japanese Pharmacopoeia) in prescriptions considered to be laxatives and laxatives. Tounin powder is commercially available from Tochimoto Tenkaido Co., Ltd., Takasago Pharmaceutical Co., Ltd., etc.

Ginseng is a ginseng of the Araliaceae family, Panax ginseng C.I. A. Meyer (Panax schinseng Needs) roots excluding fine roots or lightly boiled ones, mainly as tonic tonics, digestive promoters, antidiarrhea, tranquilizers, hypoglycemic agents as crude drugs (Japanese Pharmacopoeia) It is used for medicines, cardiotonics, antidiarrheals, anti-fatigue drugs, etc. Carrot is both a crude drug name (Japanese Pharmacopoeia) and a plant name. Carrot powder is commercially available from Nippon Powder Chemicals Co., Ltd., Tochimoto Tenkaido Co., Ltd., etc.

Takusha is a lump of Sagittaria trifolia (Alisma orientale Juzepczuk) of the water-plantain family (Alisma orientale), which is usually excluding the peripheral skin. It is used in combination with the prescription considered to be. Takusha powder is commercially available from Tochimoto Tenkaido Co., Ltd., Takasago Pharmaceutical Co., Ltd., etc.

In a preferred example of the preventive or ameliorating agent for the onset of premenstrual syndrome of the present invention, among the other crude drugs described above, at least the powder of Atractylodes lanceolata from the viewpoint of further improving the preventive or ameliorating effect of the onset of premenstrual syndrome by the present invention. And cinnamon powder, or preferably contains buttonpi powder, cinnamon powder, tounin powder, and takusha powder, and contains bukuryo powder, sojutsu powder, cinnamon powder, buttonpi powder, daiou powder, tounin powder, carrot powder, and takusha powder. It is particularly preferable to include powder.

Crude drug powder selected from the group consisting of rhubarb powder, sojutsu powder, cinnamon powder, buttonpi powder, rhubarb powder, tounin powder, carrot powder, and takusha powder in the preventive or ameliorating agent for the onset of premenstrual syndrome of the present invention (others). The content of crude drug powder) is not particularly limited, and examples thereof include 2 to 70% by weight in total.

The ratio of the total amount of other crude drug powders to the total amount of Angelica acutiloba powder, Peony powder and Senkyu powder is not particularly limited, but from the viewpoint of further enhancing the preventive or ameliorating effect of the onset of PMS, Angelica acutiloba powder, Peony powder and With respect to 100 parts by weight of the total amount of peony powder, 100 to 350 parts by weight, preferably 230 to 300 parts by weight can be mentioned.

Specifically, the content of each of the powders of other crude drugs with respect to the total amount of powders of Touki, Shakuyaku and Senkyu is not particularly limited, but from the viewpoint of further enhancing the effect of preventing or improving the onset of premenstrual syndrome, the powder of Touki, For 100 parts by weight of the total amount of the powder of Shakuyaku and the powder of Senkyu, 1 to 40 parts by weight, preferably 23 to 30 parts by weight of the powder of Bukuryo; 8 to 30 parts by weight, preferably 23 of the powder of Sojutsu. ~ 28 parts by weight; 15-40 parts by weight, preferably 20-26 parts by weight; 15-40 parts by weight, preferably 23-28 parts by weight of buttonpi powder. In the case of powdered daiou, 10 to 30 parts by weight is mentioned; in the case of powdered tounin, 8 to 40 parts by weight, preferably 10 to 20 parts by weight; in the case of powdered carrot, 1 to 50 parts by weight, preferably. 3 to 6.5 parts by weight; in the case of takusha powder, 10 to 40 parts by weight, preferably 10 to 20 parts by weight.

Other Ingredients The prophylactic or ameliorating agent for the onset of premenstrual syndrome of the present invention may further contain additives and bases according to the form of the preparation in addition to the above-mentioned crude drug ingredients. Additives and bases are not particularly limited as long as they are pharmaceutically acceptable, but excipients, binders, disintegrants, lubricants, tonicity agents, plasticizers, dispersants, emulsifiers, etc. Dissolving aids, wetting agents, stabilizers, suspending agents, pressure-sensitive adhesives, coating agents, brighteners, water, fats and oils, waxes, hydrocarbons, fatty acids, higher alcohols, esters, water-soluble High polymers, surfactants, metal soaps, lower alcohols, polyhydric alcohols, pH adjusters, buffers, antioxidants, UV inhibitors, preservatives, flavoring agents, fragrances, powders, thickeners, pigments , Chelating agent and the like. These additives may be used alone or in combination of two or more. The content of these additives and bases is appropriately set according to the types of additives and bases to be used, the form of the prophylaxis or ameliorating agent for preventing or improving the onset of premenstrual syndrome of the present invention, and the like.

Specific examples of the additives and bases include starch, lactose, carmellose calcium, light anhydrous silicic acid, magnesium stearate, synthetic aluminum silicate, magnesium aluminometasilicate, calcium silicate, magnesium silicate, and synthetic. Hydrotalcite, anhydrous calcium hydrogen phosphate, carmellose, croscarmellose sodium, sodium starch glycolate, crospopidone are mentioned, preferably carmellose calcium, light anhydrous silicic acid, magnesium stearate, and synthetic aluminum silicate. Can be mentioned. Examples of starch include potato starch, corn starch and the like, and corn starch is preferable. The contents of these additives and bases are appropriately set according to the types of additives and bases used.

When the preventive or ameliorating agent for the onset of premenstrual syndrome of the present invention further contains additives and bases in addition to the above-mentioned crude drug components, the total amount of the additives and bases to be blended in the entire pharmaceutical composition 2 to 70% by weight, preferably 5 to 60% by weight.

In addition, the preventive or ameliorating agent for the onset of premenstrual syndrome of the present invention may further contain other nutritional components and pharmacological components, if necessary. Such nutritional components and pharmacological components are not particularly limited as long as they are pharmaceutically acceptable, but for example, antacids, stomachic agents, digestive agents, intestinal regulators, antispasmodics, mucosal repair agents, anti-inflammatory agents, and antiemetics. Agents, antitussives, sputum, anti-inflammatory enzyme agents, sedative hypnotics, antihistamines, caffeines, cardiotonic diuretics, antibacterial agents, vasoconstrictors, vasodilators, local anesthetics, crude drugs and / or crude drug extracts, vitamins And so on. These nutritional components and pharmacological components may be used alone or in combination of two or more. Further, the content of these components is appropriately set according to the type of the component to be used and the like.

Formulation form The formulation form of the agent for preventing or ameliorating the onset of premenopausal syndrome of the present invention is not particularly limited as long as it can be orally administered, and is, for example, a powder, a fine granule, a capsule, a tablet, or a troche. , Chewables, capsules (soft capsules, hard capsules), rounds and other solid formulations; semi-solid formulations such as jelly; liquid formulations such as liquids, suspending agents and syrups.

Production method The method for producing a preventive or ameliorating agent for the onset of premenstrual syndrome of the present invention may be formulated by using the above-mentioned crude drug components according to a usual formulation method adopted in the pharmaceutical field.

Uses The agent for preventing or ameliorating the onset of premenstrual syndrome of the present invention is used for the purpose of preventing or ameliorating the onset of PMS in women with premenstrual syndrome (PMS).

PMS in the present invention is a mental or physical symptom that lasts during the luteal phase 3 to 10 days before menstruation, and diminishes or disappears with the onset of menstruation. Mental symptoms include frustration, anger, aggressiveness, depression, depression, fragile tears, increased anxiety, and physical symptoms include cold hands and feet, stiff neck and shoulders, and so on. Breast pain, breast tension, lower abdomen pain, lower abdomen tension, head pain, lower back pain, dullness, dizziness, palpitation, anemia, swelling, rough skin, prone to acne It is easy to get tired, has increased appetite, becomes sleepy, has constipation, and has dizziness.

Prevention of the onset of PMS means eliminating the onset of PMS, and improvement of the onset of PMS means reducing the degree of symptoms of the onset of PMS.

The agent for preventing or improving the onset of PMS of the present invention is also used for the purpose of improving the constitution of PMS for women with PMS, depending on the usage. Improving the constitution of PMS means the onset of PMS even after the prevention or ameliorating agent for the onset of PMS of the present invention is stopped and the prevention or ameliorating agent for the onset of PMS of the present invention is not taken. It means that the state where the symptom disappears or the degree of the symptom of PMS that develops is reduced is maintained.

Dosage and Usage The preventive or ameliorating agent for the onset of PMS of the present invention is used by oral administration. The dose of the preventive or ameliorating agent for the onset of premenstrual syndrome of the present invention is appropriately set according to the age, constitution, degree of symptom, etc. of the administration subject. The total amount of crude drug components is 0.3 to 7 g, preferably 1.8 to 5.5 g, more preferably 2.2 to 4 g, and the total amount of touki powder, symptomatological powder, and senkyu powder is 0. .1 to 1.5 g, preferably 0.5 to 1.2 g, more preferably 0.7 to 0.9 g. In addition, the preventive or ameliorating agent for the onset of PMS of the present invention can be taken 1 to 3 times a day, preferably 2 or 3 times, more preferably 3 times a day. The timing of administration is not particularly limited and may be before meals, after meals, or between meals, but it is preferably after meals.

The schedule for taking the preventive or ameliorating agent for the onset of PMS of the present invention is not particularly limited as long as it is taken before the onset of PMS, but in view of the onset of PMS from the latter half of the luteal phase, the follicular phase. It is preferable to start administration from any day during the ovulation phase. From the viewpoint of further improving the preventive or ameliorating effect of the onset of premenstrual syndrome according to the present invention, it is preferable to start the administration at an earlier stage of the menstrual cycle. Therefore, in a preferable example of the administration schedule of the preventive or ameliorating agent for the onset of premenstrual syndrome of the present invention, it is preferable to start the administration from any day in the follicular phase, and from the start of the follicular phase (immediately after the end of menstruation). ) It is more preferable to start administration. The follicular phase, ovulation phase and luteal phase are determined by the individual's menstrual cycle.

Regarding the period of taking the preventive or ameliorating agent for the onset of premenstrual syndrome of the present invention, it should be taken every day before the onset of premenstrual syndrome, and at least at the end of the luteal phase in the menstrual cycle in which the administration was started (before the start of menstruation). ) Is preferably taken continuously. From the viewpoint of further improving the preventive or ameliorating effect of the onset of premenstrual syndrome according to the present invention, it is preferable to take it continuously for two or more cycles of the menstrual cycle every day. Furthermore, from the viewpoint of improving the constitution of PMS, it is preferable to take it continuously every day for 3 or more cycles of the menstrual cycle.

Hereinafter, the present invention will be specifically described with reference to Examples, but the present invention is not limited to these Examples.

Test Example 1
(1) Preparation of preventive or ameliorating agent for the onset of premenstrual syndrome The test drug was prepared at the compounding ratio shown in Table 1 (daily dose for humans).

(2) Test method 1
(2-1) Example 1: Use for prevention or improvement of PMS onset (taken from the start of the follicular phase to the end of the luteal phase)
The administration schedule of 23 adult female monitors with PMS symptoms is shown in FIG. From the start date of the previous menstruation (0 menstruation) to the start of the next menstruation (1st menstruation) (the 0th cycle of the menstrual cycle), the monitor records the basal body temperature without taking the test drug and records the menstrual cycle. And recorded the specific symptoms of PMS. From the end of menstruation 1 (that is, the start of the follicular phase) to the start of the next menstruation (that is, the end of the luteal phase) (that is, the first cycle of the luteal phase), the monitor takes 1 test drug daily. It was taken with water or hot water after each meal at a frequency of 3 times a day.

(2-2) Comparative Example 1: PMS improvement application (taken from the latter half of the luteal phase to the end of the luteal phase)
The administration schedule of eight adult female monitors with PMS symptoms is shown in FIG. From the start date of the previous menstruation (0 menstruation) to the start of the next menstruation (1st menstruation) (the 0th cycle of the menstrual cycle), the monitor records the basal body temperature without taking the test drug and records the menstrual cycle. And recorded the specific symptoms of PMS. In the menstrual cycle starting from menstruation 1 (the first cycle of the menstrual cycle), the monitor is used from one week before the predicted date of the next menstruation (menstruation 2) (that is, the latter half of the luteal phase) until the start of menstruation 2 (that is, the luteal phase). Until the end), the test drug was taken daily between meals three times a day.

(3) Confirmation of PMS symptoms 1
The monitors of Example 1 and Comparative Example 1 were surveyed for the presence or absence of PMS symptoms in the 0th cycle of the menstrual cycle and the presence or absence of PMS symptoms in the 1st week of the menstrual cycle. The results are shown in Table 2. In Table 2, the number of people who answered that they had each PMS symptom (number of complainants (persons)) and the number of complainants before taking the drug were effective for the PMS symptom (that is, the degree of PMS symptom). The ratio of the number of people who answered that the PMS symptom was reduced or disappeared (effective rate 1 (%)), and the ratio of the number of people who answered that the PMS symptom disappeared by taking the drug (effective rate) to the number of complainants before taking the drug. 2 (%)) is shown.

As shown in Table 2, the efficacy rate 1 of Example 1 with respect to the efficacy rate 1 of Comparative Example 1, the use of the test drug for the prevention or amelioration of the onset of PMS significantly suppressed the symptoms of PMS. confirmed. Furthermore, as shown in the efficacy rate 2 of Example 1, some monitors showed a particularly remarkable effect that the test drug not only reduced the PMS symptom but also eliminated the PMS symptom.

(3) Test method 2
Twenty-three monitors who performed Example 1 of the above test method 1 took the test drug every day until the end of the third cycle of the menstrual cycle, and took the test drug at all in the fourth week of the menstrual cycle, following the test method 1. Did not (Example 2). The dosing schedule of the monitor in Example 2 is shown in FIG.

(4) Confirmation of PMS symptoms 2
The monitor of Example 2 was surveyed for the presence or absence of PMS symptoms in each menstrual cycle. Table 3 shows the ratio of the number of people who answered that the PMS symptom disappeared by taking the drug (effective rate 2 (%)) to the number of complainants before taking the drug.

As shown in Table 3, the proportion of people who have lost PMS symptoms due to continued administration varies, but PMS is not taken at all in the 4th cycle of the menstrual cycle. There were even cases in which the disappearance of symptoms continued. In addition, in most PMS symptoms, the efficacy rate in the 4th cycle in which the test drug was not taken was higher (or equivalent) than the efficacy rate during the period of administration, and the test drug of the present invention showed a high PMS onset preventive effect. I was able to confirm that. As described above, it was confirmed that continuous administration of the test drug of the present invention can even improve the constitution in which PMS symptoms do not occur.

Claims (5)

A preventive or ameliorating agent for the onset of premenstrual syndrome, which contains powdered Angelica acutiloba, powdered peony, and powdered peony. The preventive or ameliorating agent for the onset of premenstrual syndrome according to claim 1, wherein administration is started from any day from the follicular phase to the ovulation phase. The preventive or ameliorating agent for the onset of premenstrual syndrome according to claim 1 or 2, which is a constitution improving agent for premenstrual syndrome. The agent for preventing or ameliorating the onset of premenstrual syndrome according to claim 3, which is taken continuously for 3 or more cycles of the menstrual cycle. The menstrual syndrome according to any one of claims 1 to 4, further containing a crude drug powder selected from the group consisting of rhubarb powder, sojutsu powder, cinnamon powder, buttonpi powder, rhubarb powder, tounin powder, carrot powder, and takusha powder. A preventive or ameliorating agent for the onset of premenstrual syndrome.

Images